Terapia gênica: o que é, o que não é e o que será (2024)

1. AIUTI A., Gene therapy for immunodeficiency due to adenosine deaminase deficiency, N. Engl. J. Med., № 360, с. 447
   https://doi.org/10.1056/NEJMoa0805817
2. AIUTI A., Ten years of gene therapy for primary immune deficiencies, Hematology Am. Soc. Hematol. Educ. Program, с. 682
   https://doi.org/10.1182/asheducation-2009.1.682
3. ANDERSON W. F., Human gene therapy: the initial concepts, с. 3
4. ANDERSON W. F., The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, Hum Gene Ther, № 1, с. 331
5. ANDREWES C., Richard Edwin Shope, № 50, с. 352
6. ANDREWES C. H., Rhinoviruses and common colds, Annu. Rev. Med., № 17, с. 361
   https://doi.org/10.1146/annurev.me.17.020166.002045
7. ATKINS G .J., Therapeutic and prophylactic applications of alphavirus vectors, Expert. Ver. Mol. Med., № 10, с. e33
   https://doi.org/10.1017/S1462399408000859
8. BAGLEY J., Gene therapy in type 1 diabetes, Crit. Rev. Immunol., № 28, с. 301
   https://doi.org/10.1615/CritRevImmunol.v28.i4.30
9. BAINBRIDGE J. W., Effect of gene therapy on visual function in Leber's congenital amaurosis, N. Engl. J. Med., № 358, с. 2231
   https://doi.org/10.1056/NEJMoa0802268
10. BAUZON M., Exploiting diversity: genetic approaches to creating highly potent and efficacious oncolytic viruses, Curr. Opin. Mol. Ther., № 10, с. 350
11. BERETA G., Impact of retinal disease-associated RPE65 mutations on retinoid isomerization, Biochemistry, № 47, с. 9856
    https://doi.org/10.1021/bi800905v
12. BLAESE R. M., T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years, Science, № 270, с. 475
    https://doi.org/10.1126/science.270.5235.475
13. BOBROW M., Patenting DNA, Curr. Opin. Mol. Ther., № 4, с. 542
14. BRAAK H, Assessing fetal nerve cell grafts in Parkinson's disease, Nat. Med., № 14, с. 483
    https://doi.org/10.1038/nm0508-483
15. BRINKMAN R. R., Human monogenic disorders - a source of novel drug targets, Nat. Rev. Genet., № 7, с. 249
    https://doi.org/10.1038/nrg1828
16. BUCKLEY R. H., Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution, Annu. Rev. Immunol., № 22, с. 625
    https://doi.org/10.1146/annurev.immunol.22.012703.104614
17. CACABELOS R., Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression, Methods Find Exp. Clin. Pharmacol., № 29, с. 1
18. CARDONE M., Prospects for gene therapy in inherited neurodegenerative diseases, Curr. Opin. Neurol., № 20, с. 151
    https://doi.org/10.1097/WCO.0b013e32809f97ff
19. CATTANEO R., Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded, Nat. Ver. Microbiol., № 6, с. 529
    https://doi.org/10.1038/nrmicro1927
20. CAVAZZANA-CALVO M., Gene therapy for severe combined immunodeficiency: are we there yet, J. Clin. Invest., № 117, с. 1456
    https://doi.org/10.1172/JCI30953
21. CEMAZAR M., Electrotransfer of therapeutic molecules into tissues, Curr. Opin. Mol. Ther., № 9, с. 554
22. CHEN Q., Gene therapy for Parkinson's disease: progress and challenges, Curr. Gene Ther., № 5, с. 71
    https://doi.org/10.2174/1566523052997505
23. CHRISTINE C. W., Safety and tolerability of putaminal AADC gene therapy for Parkinson disease, Neurology, № 73, с. 1662
    https://doi.org/10.1212/WNL.0b013e3181c29356
24. CIDECIYAN A. V., Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics, Proc. Natl. Acad. Sci., № 105, с. 15112
    https://doi.org/10.1073/pnas.0807027105
25. CLANCHY F. I., Plasmid DNA as a safe gene delivery vehicle for treatment of chronic inflammatory disease, Expert Opin. Biol. Ther., № 8, с. 1507
    https://doi.org/10.1517/14712598.8.10.1507
26. COLEMAN W. B.
27. CULVER K. W., Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer, Transplant Proc., № 23, с. 170
28. DASS C. R., Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection, J. Mol. Med., № 82, с. 579
29. DAUER W., Parkinson's disease: mechanisms and models, Neuron, № 39, с. 889
    https://doi.org/10.1016/S0896-6273(03)00568-3
30. DAWSON T. M., Molecular pathways of neurodegeneration in Parkinson's disease, Science, № 302, с. 819
    https://doi.org/10.1126/science.1087753
31. HOLLANDER A. I., Prog. Retin Eye Res., № 27, с. 391
    https://doi.org/10.1016/j.preteyeres.2008.05.003
32. DIAMOND A., J. Neurol. Neurosurg Psychiatry, № 76, с. 1188
    https://doi.org/10.1136/jnnp.2005.065334
33. DORMOND E., From the first to the third generation adenoviral vector: what parameters are governing the production yield, Biotechnol. Adv., № 27, с. 133
    https://doi.org/10.1016/j.biotechadv.2008.10.003
34. EINSTEIN O, The changing face of neural stem cell therapy in neurologic diseases, Arch. Neurol., № 65, с. 452
    https://doi.org/10.1001/archneur.65.4.452
35. EVAN G., A matter of life and cell death, Science, № 281, с. 1317
    https://doi.org/10.1126/science.281.5381.1317
36. FAVARD C., Electrotransfer as a non viral method of gene delivery, Curr. Gene. Ther., № 7, с. 67
    https://doi.org/10.2174/156652307779940207
37. FISCHER A, Gene therapy of inherited diseases, Lancet, № 371, с. 2044
    https://doi.org/10.1016/S0140-6736(08)60874-0
38. FJORD-LARSEN L., Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct, Exp. Neurol., № 195, с. 49
    https://doi.org/10.1016/j.expneurol.2005.03.006
39. FLOTTE T. R., Gene therapy: the first two decades and the current state-of-the-art, J. Cell. Physiol., № 213, с. 301
    https://doi.org/10.1002/jcp.21173
40. FRIEDMANN T., The road toward human gene therapy--a 25-year perspective, Ann Med., № 29, с. 575
    https://doi.org/10.3109/07853899709007485
41. Mol Ther, № 4, с. 285
    https://doi.org/10.1006/mthe.2001.0454
42. GASPAR H. B., Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector, Lancet, № 364, с. 2181
    https://doi.org/10.1016/S0140-6736(04)17590-9
43. GAUTHIER S., Current and future management of Alzheimer's disease, Alzheimers Dement., № 4, с. S48
    https://doi.org/10.1016/j.jalz.2007.11.010
44. GILL D. R., Progress and prospects: the design and production of plasmid vectors, Gene Ther., № 16, с. 165
    https://doi.org/10.1038/gt.2008.183
45. GOLDSTEIN M., Decade of the brain: an agenda for the nineties, West. J. Med., № 161, с. 239
46. GREEN D. R., A matter of life and death., Cancer Cell., № 1, с. 19
    https://doi.org/10.1016/S1535-6108(02)00024-7
47. GRIBBEN J. G., Stem cell transplantation in chronic lymphocytic leukemia, Biol. Blood Marrow Transplant., № 15, с. 53
    https://doi.org/10.1016/j.bbmt.2008.10.022
48. GUTTMAN M., Current concepts in the diagnosis and management of Parkinson's disease, CMAJ, № 168, с. 293
49. HACEIN-BEY-ABINA S., Gene therapy of X-linked severe combined immunodeficiency, Int. J. Hematol., № 76, с. 295
    https://doi.org/10.1007/BF02982686
50. HACEIN-BEY-ABINA S., LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1, Science, № 302, с. 415
    https://doi.org/10.1126/science.1088547
51. HAN J. J., Diagnosis and clinical management of spinal muscular atrophy, Phys. Med. Rehabil. Clin. N. Am., № 19, с. 661
    https://doi.org/10.1016/j.pmr.2008.02.004
52. HASBROUCK N. C., AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects, Gene Ther., № 15, с. 870
    https://doi.org/10.1038/gt.2008.71
53. HAUSER O., Encapsulated, genetically modified cells producing in vivo therapeutics, Curr. Opin. Mol. Ther, № 6, с. 412
54. HAUSWIRTH W, Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial, Hum. Gene. Ther., № 19, с. 979
    https://doi.org/10.1089/hum.2008.107
55. HERWEIJER H., Gene therapy progress and prospects: hydrodynamic gene delivery, Gene Ther., № 14, с. 99
    https://doi.org/10.1038/sj.gt.3302891
56. HOWE S. J., Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin Invest., № 118, с. 3143
    https://doi.org/10.1172/JCI35798
57. IMMONEN A., AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study, Mol. Ther., № 10, с. 967
    https://doi.org/10.1016/j.ymthe.2004.08.002
58. JACKSON D. A., Biochemical method for inserting new genetic information into DNA of Simian Virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli, Proc. Natl. Acad. Sci, № 69, с. 2904
    https://doi.org/10.1073/pnas.69.10.2904
59. JALBERT J. J., Dementia of the Alzheimer type., Epidemiol. Rev., № 30, с. 15
    https://doi.org/10.1093/epirev/mxn008
60. KANG U. J., Gene therapy for Parkinson's disease: determining the genes necessary for optimal dopamine replacement in rat models, Hum. Cell., № 14, с. 39
61. KAPLITT M. G., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial, Lancet, № 369, с. 2097
    https://doi.org/10.1016/S0140-6736(07)60982-9
62. KOHN D. B., Gene therapy fulfilling its promise, N. Engl. J. Med., № 360, с. 518
    https://doi.org/10.1056/NEJMe0809614
63. KORDOWER J. H., Nat, Med., № 14, с. 504
64. LANDER E. S., Initial sequencing and analysis of the human genome, Nature, № 409, с. 860
    https://doi.org/10.1038/35057062
65. LI J. Y., Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation, Nat. Med., № 14, с. 501
    https://doi.org/10.1038/nm1746
66. LINDEN R., с. 128p
67. LINDEN R., с. 205
68. LINDVALL O., Encapsulated cell biodelivery of GDNF: a novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?, Exp. Neurol., № 209, с. 82
    https://doi.org/10.1016/j.expneurol.2007.08.019
69. LUNDBERG C., Applications of lentiviral vectors for biology and gene therapy of neurological disorders, Curr. Gene Ther., № 8, с. 461
    https://doi.org/10.2174/156652308786847996
70. LUO J., Subthalamic GAD gene therapy in a Parkinson's disease rat model., Science, № 298, с. 425
    https://doi.org/10.1126/science.1074549
71. MACHIDA C. A.
72. MAGUIRE A. M., Safety and efficacy of gene transfer for Leber's congenital amaurosis, N. Engl. J. Med., № 358, с. 2240
    https://doi.org/10.1056/NEJMoa0802315
73. MANNO C. S., AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B., Blood, № 101, с. 2963
    https://doi.org/10.1182/blood-2002-10-3296
74. MANNO C. S., Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response, Nat. Med., № 12, с. 342
    https://doi.org/10.1038/nm1358
75. MARKS W. J., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial, Lancet Neurol., v.7, с. 400
    https://doi.org/10.1016/S1474-4422(08)70065-6
76. MENDEZ I., Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years., Nat. Med., № 14, с. 507
    https://doi.org/10.1038/nm1752
77. MERCOLA K. E., Sounding boards. The potentials of inserting new genetic information, N. Engl. J. Med., № 303, с. 1297
    https://doi.org/10.1056/NEJM198011273032211
78. MINGOZZI F., Immune responses to AAV in clinical trials, Curr. Gene Ther., № 7, с. 316
    https://doi.org/10.2174/156652307782151425
79. MULLEN C. A., Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector, Hum. Gene Ther., № 7, с. 1123
    https://doi.org/10.1089/hum.1996.7.9-1123
80. MUUL L. M., Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial, Blood, № 101, с. 2563
    https://doi.org/10.1182/blood-2002-09-2800
81. NAKANO K., Neural circuits and topographic organization of the basal ganglia and related regions, Brain Dev., № 22, Suppl. 1, с. S5
    https://doi.org/10.1016/S0387-7604(00)00139-X
82. NATHWANI A. C., A review of gene therapy for haematological disorders, Br. J. Haematol., № 28, с. 3
    https://doi.org/10.1111/j.1365-2141.2004.05231.x
83. O'CONNOR T. P., Genetic medicines: treatment strategies for hereditary disorders, Nat. Rev. Genet., № 7, с. 261
    https://doi.org/10.1038/nrg1829
84. OLANOW C. W., Why have we failed to achieve neuroprotection in Parkinson's disease?, Ann Neurol., № 64, с. S101
    https://doi.org/10.1002/ana.21461
85. PARDRIDGE W. M., Tyrosine hydroxylase replacement in experimental Parkinson's disease with transvascular gene therapy, NeuroRx., № 2, с. 129
    https://doi.org/10.1602/neurorx.2.1.129
86. PARDRIDGE W. M., Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses, J. Control. Release, № 122, с. 345
    https://doi.org/10.1016/j.jconrel.2007.04.001
87. PEARSON S., China approves first gene therapy, Nature Biotechnol., № 22, с. 3
    https://doi.org/10.1038/nbt0104-3
88. с. 26
89. POEHNER W. J., A hom*ozygous deletion in RPE65 in a small Sardinian family with autosomal recessive retinal dystrophy, Mol. Vis., № 6, с. 192
90. POEWE W., Treatments for Parkinson disease - past achievements and current clinical needs, Neurology, № 72, с. S65
    https://doi.org/10.1212/WNL.0b013e31819908ce
91. PORTEUS M. H., A look to future directions in gene therapy research for monogenic diseases, PLoS Genet., № 2, с. e133
    https://doi.org/10.1371/journal.pgen.0020133
92. PROCHOWNIK E. V., c-Myc: linking transformation and genomic instability, Curr. Mol. Med., № 8, с. 446
    https://doi.org/10.2174/156652408785747988
93. RADUNOVIC A., Clinical care of patients with amyotrophic lateral sclerosis, Lancet Neurol., v.6, с. 913
    https://doi.org/10.1016/S1474-4422(07)70244-2
94. RAINOV N. G., Gene therapy for human malignant brain tumors, Cancer J., № 9, с. 180
    https://doi.org/10.1097/00130404-200305000-00006
95. RAPER S. E., Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer, Mol. Genet. Metab., № 80, с. 148
    https://doi.org/10.1016/j.ymgme.2003.08.016
96. RAPER S. E., Developing adenoviral-mediated in vivo gene therapy for ornithine transcarbamylase deficiency., J. Inherit Metab. Dis., № 21, Suppl. 1, с. 119
    https://doi.org/10.1023/A:1005369926784
97. RÄTY J. K., Improving safety of gene therapy, Curr. Drug Saf., № 3, с. 46
    https://doi.org/10.2174/157488608783333925
98. REFFELMANN T, Promise of blood- and bone marrow-derived stem cell transplantation for functional cardiac repair: putting it in perspective with existing therapy, J. Am. Coll. Cardiol., № 53, с. 305
    https://doi.org/10.1016/j.jacc.2008.10.018
99. RIBACKA C., Cancer, stem cells, and oncolytic viruses., Ann. Med., № 40, с. 496
    https://doi.org/10.1080/07853890802021342
100. ROGERS S., Joint action of a chemical carcinogen and a neoplastic virus to induce cancer in rabbits; results of exposing epidermal cells to a carcinogenic hydrocarbon at time of infection with the Shope papilloma virus, J. Exp. Med., № 93, с. 459
     https://doi.org/10.1084/jem.93.5.459
101. ROGERS S., Serial transplantation of rabbit papillomas caused by the Shope virus., J. Exp. Med., № 95, с. 543
     https://doi.org/10.1084/jem.95.6.543
102. SANVICENS N., Multifunctional nanoparticles--properties and prospects for their use in human medicine, Trends Biotechnol., № 26, с. 425
     https://doi.org/10.1016/j.tibtech.2008.04.005
103. SCAGLIA F., Clinical, biochemical, and molecular spectrum of hyperargininemia due to arginase I deficiency, Am. J. Med. Genet. C. Semin. Med. Genet., № 142C, с. 113
     https://doi.org/10.1002/ajmg.c.30091
104. SILVA C. L., Recent advances in DNA vaccines for autoimmune diseases, Expert Rev. Vaccines, № 8, с. 239
     https://doi.org/10.1586/14760584.8.2.239
105. SYKES K., Progress in the development of genetic immunization, Expert Rev. Vaccines, № 7, с. 1395
     https://doi.org/10.1586/14760584.7.9.1395
106. THAJEB P., The effects of storage conditions and trophic supplementation on the survival of fetal mesencephalic cells, Cell Transplant., № 6, с. 297
     https://doi.org/10.1016/S0963-6897(97)00034-1
107. TORRENTE Y., Mesenchymal stem cell transplantation for neurodegenerative diseases, Cell Transplant., № 17, с. 1103
     https://doi.org/10.3727/096368908787236576
108. Van der SPUY J., Predominant rod photoreceptor degeneration in Leber congenital amaurosis, Mol Vis., № 11, с. 542
109. VAZQUEZ A., The genetics of the p53 pathway, apoptosis and cancer therapy, Nat. Rev. Drug Discov., № 7, с. 979
     https://doi.org/10.1038/nrd2656
110. VELLAI T., The origin of eukaryotes: the difference between prokaryotic and eukaryotic cells, Proc. Biol. Sci., № 266, с. 1571
     https://doi.org/10.1098/rspb.1999.0817
111. VENTER J. C., The sequence of the human genome., Science, № 291, с. 1304
     https://doi.org/10.1126/science.1058040
112. VOSS C., Production of plasmid DNA for pharmaceutical use., Biotechnol. Annu. Rev., № 13, с. 201
     https://doi.org/10.1016/S1387-2656(07)13008-8
113. WANG X., Mitotic checkpoint defects in human cancers and their implications to chemotherapy, Front Biosci., № 13, с. 2103
     https://doi.org/10.2741/2827
114. WATSON J. D.
115. WU C., Inclusion of high molecular weight dextran in calcium phosphate-mediated transfection significantly improves gene transfer efficiency, Cell. Mol. Biol., № 53, с. 67
116. YI Y., Retroviral gene therapy: safety issues and possible solutions, Curr. Gene Ther., № 5, с. 25
     https://doi.org/10.2174/1566523052997514

GENE THERAPY – THE FUTURE OF MEDICINE

o Krishnasai Reddy, S P Srinivas Nayak, Puvvula Vijaya Durga, Swapna Kannabathula, Tarun Kumar Upadhyay

https://doi.org/10.36106/paripex/8005576

Biological products in medicine

Marzieh Daniali, Taraneh Mousavi, Mohammad Abdollahi

https://doi.org/10.1016/b978-0-12-824315-2.00039-7

Gene therapy and its applications

Uma Advani, Alka Bansal, Ravi Prakash, Swati Agarwal

https://doi.org/10.4103/jme.jme_65_21

Recent Advances in Nanocarriers Used for Selective Gene Silencing Therapy

Fabíola Silva Garcia Praça, Lívia Neves Borgheti-Cardoso, Margarete Moreno de Araújo, Maria Vitória Lopes Badra Bentley

https://doi.org/10.1007/978-3-030-63389-9_9

Gene Therapy for Chronic Traumatic Brain Injury: Challenges in Resolving Long-term Consequences of Brain Damage

Vipin V. Dhote, Prem Samundre, Aman B. Upaganlawar, Aditya Ganeshpurkar

https://doi.org/10.2174/1566523221666211123101441 ·

Gene-environment interactions that influence CVD, lipid traits, obesity, diabetes, and hypertension appear to be able to influence gene therapy

Moataz Dowaidar

https://doi.org/10.1016/j.mam.2023.101213

Advances in gene therapy approaches targeting neuro-inflammation in neurodegenerative diseases

Kuldeep Singh, Pranshul Sethi, Samaresh Datta, Jitendra Singh Chaudhary, Sunil Kumar, Divya Jain, Jeetendra Kumar Gupta, Shivendra Kumar, Ajay Guru, Siva Prasad Panda

https://doi.org/10.1016/j.arr.2024.102321 ·

About this publication